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Abstract
Background: Fecal elastase-1 (E1) test is a sensitive and specific indirect test. However, there are few data on the best cut-off
level in the assessment of exocrine pancreatic function in cystic fibrosis (CF). Material and methods: In 725 CF patients and
243 healthy subjects (HS) from Greece, Russia, Poland and the United Kingdom, E1 concentrations were measured. The best
cut-off levels for the discrimination between CF and HS (for whole group as well as for individual countries) were calculated.
Results: The best cut-off level for the differentiation between CF pancreatic insufficiency and normal pancreatic function in HS
was found to be 184 mgyg of feces. However, some inter-country differences were stated. E1 concentrations in the UK subgroup
were significantly lower than those found in Polish and Russian CF patients. E1 concentrations in Greek patients were significantly
higher than in the other countries. However, E1 concentrations in DF508 homozygotes were very similar in all studied subgroups.
In conclusion: In clinical practice, instead of a single best cut-off level for the E1 test, we suggest using a range of values (160–
200 mgyg). The presence of different best cut-off levels within countries is a practical consequence of the different distribution
of pancreatic function.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The assessment of exocrine pancreatic function is one
of the major diagnostic procedures in the investigation
of gastrointestinal disease in cystic fibrosis (CF). Exo-
crine pancreatic function can be assessed by either direct
Abbreviations: CF, cystic fibrosis; HS, healthy subjects; E1, fecal
elastase-1; GR, Greece; PL, Poland; RU, Russia; UK, United
Kingdom.
 Part of the data has been presented at 24th European Cystic
Fibrosis Conference, Vienna 6–9 June 2001. (Walkowiak J, Nousia-
Arvanitakis S, Kashirskaya N et al. Fecal elastase-1 cut-off levels in
the assessment of exocrine pancreatic function in cystic fibrosis: a
multicenter study. Journal of Cystic Fibrosis. 2001; A130.)
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or indirect methods, with the direct tests, such as the
secretin–cholecystokinin test having the highest sensi-
tivity and specificity w1x. However, direct tests have
some major disadvantages, which make them unsuitable
for routine evaluation in children, especially in those
with CF. Indirect tests are more frequently used in
clinical practice because they are non-invasive, simple,
less time-consuming and less expensive.
The development of new indirect tests has improved
the diagnostic approach. From previous studies, the
measurement of fecal elastase-1 (E1) concentration
appears to be a good measure of pancreatic function
w2–4x. The enzyme is highly specific for the pancreas
and is not degraded during intestinal passage w5x. E1
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Table 1
E1 concentrations (mgyg of feces) in HS
Subjects (n) HS-all HS-GR HS-PL HS-UK
243 78 105 44
Age (years) Mean"S.E.M. 11.2"0.5 10.5"0.3 13.3"0.5 7.3"1.5
Range 0.1–52.1 2.00–23.00 0.17–40.00 0.1–52.1
E1 (mgyg)a Mean"S.E.M. 636.7"22.0 454.2"9.1 753.3"29.9 680.3"34.7
Median 570 464 714 704
Range 167–1802 205–720 167–1802 167–1255
Russian values were not included (ns16; E1s1054, 736, 662, 551 and 12x)500), since they did not allow for any calculations.a
No age-related differences in E1 concentrations were found. Therefore, the analysis was performed without age subgroup distribution. GR vs.
PL, UK P-0.001.
Table 2
E1 concentrations (mgyg of feces) in CF patients
Patients (n) CF-all CF-GR CF-PL CF-UK CF-RU
725 78 414 136 97
Age (years) Mean"S.E.M. 10.1"0.2 15.2"0.8 10.2"0.3 7.8"0.4 9.2"0.5
Range 0.1–30.8 1.0–30.0 0.1–30.8 0.1–20.8 0.3–20.0
E1 (mgyg)a Mean"S.E.M. 90.6"8.3 119.5"18.6 98.5"12.7 48.4"12.5 94.0"21.0
Median 17 46 16 10 18
Range 0–1810 4–742 0–1810 0–935 0–1036
GR vs. PL, RU, UK P-0.001.a
UK vs. GR, PL P-0.05.
concentration is significantly correlated to duodenal
elastase-1 output w4,6x, daily variations are low w3x and
no degradation over a period of 1 week at room
temperature has been reported w3,4x. In addition, the
monoclonal antibodies against human pancreatic elastase
do not cross-react with pancreatic preparations of animal
origin making it unnecessary to discontinue enzyme
replacement therapy in subjects studied w4x.
Previous studies evaluating the E1 test have generally
recruited CF patients with severe exocrine pancreatic
insufficiency and small groups of healthy subjects (HS)
as controls w7,8x. In larger studies, the best cut-off level
has not been calculated w9,10x. A value of 200 mgyg of
feces is commonly used for determining exocrine pan-
creatic insufficiency, although there are few data con-
cerning CF patients w4,11x. The aim of the present study
is to calculate the best cut-off level for E1 in the
assessment of pancreatic exocrine function in CF
patients and healthy controls. The ‘distribution’ of pan-
creatic function in CF patients from different European
countries has been examined to assess the variability of
E1 values dependent upon genetic background.
2. Material and methods
2.1. Patients
Seven hundred and twenty five CF patients (357
females and 368 males) aged 2 months to 31 years
wmean"S.E.M. (standard error of the mean): 10.1"0.2x
were evaluated. The diagnosis of CF was based on
clinical manifestations, chloride sweat concentrations)
60 meqyl and CFTR gene analysis. Two hundred and
forty three children, adolescents and adults (130 females
and 113 males) aged 2 months to 52 years
(mean"S.E.M.: 11.2"0.5) without gastrointestinal dis-
ease served as a control group. All subjects included in
the study were from Greece (GR), Poland (PL), Russia
(RU) and the United Kingdom (UK) (Tables 1 and 2).
The best cut-off levels for the discrimination between
CF and HS were calculated. All calculations were
performed for both the whole CF and HS groups as
well as for individual countries (GR, PL and UK). The
effect of the different ‘distribution of pancreatic func-
tion’ on the best cut-off level in the different countries
was assessed by comparison with the whole group of
HS.
The local ethics committees in each study center
approved the protocol for this study.
2.2. Methods
E1 concentrations (mgyg of feces) were measured in
all subjects by an enzyme-linked immunosorbent assay
(ELISA; ScheBo Tech, Giessen, Germany) w12x. As
pancreatic involvement in CF has a progressive character
w13x, patients under the age of 2 years were recruited to
the study only if they had low E1 value (-50 mgyg).
Since normal reference values are not applicable to
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Table 3
DF508 frequency in CF patients
CF-all CF-GR CF-PL CF-UK CF-RU
Frequency (%) DF508 homozygotes 33.9 19.2 38.1 65.4 33.3
DF508 allele 55.8 46.6 58.9 79.0 59.2
Table 4
E1 concentrations (mgyg of feces) in DF508 homozygotes and in
other patients
DF508 homozygotes Other patients
Mean"S.E.M. Median Mean"S.E.M. Median
All 16.2"1.2 11 142.7"10.3 24
GR 16.2"4.3 14 144.9"22.2 83
PL 15.0"1.2 12 153.0"19.7 22
UK 18.3"3.0 9 103.5"33.8 18
RU 13.3"1.8 16 140.0"29.4 21
DF508 homozygotes: n.s. Other patients: GR vs. PL, UK, RU P-
0.001.
Table 5
Best cut-off levels of E1 in the assessment of exocrine pancreatic
function (CF patients with exocrine pancreatic insufficiency vs. HS)
CF patients vs. Individual country vs. Whole HS group
HS subgroup
Alla – 184
GR 203 201
PL 174 183
UK 161 161
Russian values included (E1s1054, 734, 662, 551 and 12x)a
500).
neonates w14x, HS younger than 1 month were excluded
from the study.
3. Statistical analysis
The statistical differences between groups were cal-
culated using the Kruskal–Wallis test with post test.
The level of significance was set at P-0.05.
The best cut-off levels between CF patients and HS
were calculated with the use of Odds ratio.
4. Results
The range of E1 concentrations in HS was from 167
to 1802 mgyg of feces (Table 1). The overall specificity
of the E1 test was 98.8% for the best cut-off level
calculated in the present study (184 mgyg) and 97.5%
for the best cut-off level recommended by the manufac-
turer (200 mgyg). The distribution of E1 results was
very similar in British and Polish subgroups. However,
E1 concentrations found in the HS Greek population
were significantly lower (P-0.001).
The range for E1 concentrations in CF patients was
from undetectable to 1810 mgyg feces (Table 2). The
overall sensitivity was 88.1 and 89.1% for own and
‘commercial’ cut-off level, respectively. The distribution
of E1 results was very similar in Polish and Russian
subgroups. E1 concentrations in UK subgroup were
significantly lower than those found in Polish and
Russian subjects (P-0.05). E1 concentrations in Greek
patients were significantly higher than in the other
countries (P-0.001 in all cases).
The frequency of the DF508 mutation was the highest
among British and the lowest among Greek patients
(Table 3). E1 concentrations in DF508 homozygotes
were very similar in all studied subgroups. The distri-
bution of E1 results in other CF patients was similar in
British, Polish and Russian patients. In Greek popula-
tion, however, E1 concentrations were significantly high-
er than in the other subgroups (P-0.001 in all cases)
(Table 4).
With the use of E1 test, the best cut-off level for the
differentiation between CF pancreatic insufficiency and
normal pancreatic function in HS was 184 mgyg of
feces. This level was different for each country (Table
5). The highest value was found for Greek population
(203 mgyg), an intermediate value for Polish (174 mgy
g) and the lowest for the British subgroup (161 mgyg).
For the calculation performed in relation to the whole
HS group, similar inter-country differences were
observed Table 5.
5. Discussion
There are only two studies w4,11x, in which the best
cut-off level for E1 has been previously assessed. In
that of Stein et al. w4x, the optimal discrimination was
found for a cut-off level of 175 mgyg. However, the
study was based on non-homogenous groups of patients,
comprising CF and chronic pancreatitis patients (ns54)
as well as HS (ns53) and patients with non-pancreatic
disorders (ns57). Walkowiak w11x in a larger CF group
(ns91) defined the best cut-off level at 198 mgyg.
However, the percentage (17.6%) of pancreatic suffi-
cient patients incorporated within the study was high.
For this present study, we have included a large cohort
of CF patients and HS from different European coun-
tries. A value of 184 mgyg was found as a best cut-off
level for the E1 test to differentiate between pancreatic
insufficiency in CF and normal pancreatic function in
HS. However, we have found some minor inter-country
differences. Therefore, we would suggest, in clinical
practice, using a range of values for E1 (for simplifi-
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cation 160–200 mgyg), rather than a single cut-off
value, below which further investigation of pancreatic
exocrine function is warranted.
The genotype predicts with a high probability the
course of pancreatic disease in CF. Patients who carry
two ‘severe’ mutations develop pancreatic insufficiency,
whereas those who carry at least one ‘mild’ mutation
usually remain pancreatic sufficient w15x. Therefore, the
variable distribution of pancreatic function measured as
an output of E1 in populations with different DF508
frequency stated in the present study is reasonable. The
presence of different best cut-off levels is a practical
consequence of this finding. Since no differences for
DF508 homozygous patients were found, the higher E1
concentrations found in Greek population could be
explained by the more common presence of mild muta-
tions w15–18x.
In the present study, the percentage of CF patients
(11.3%) found to have normal pancreatic function
(assessed with the use of E1 test) is higher than in
earlier studies assessing the applicability of the E1 test
w7,8x. However, we have included complete CF popu-
lations comprising both pancreatic insufficient and suf-
ficient patients.
In CF, the concentration of chloride, bicarbonate and
water in pancreatic fluid is markedly decreased w19x.
However, the amount of secreted enzymes differs sig-
nificantly. Exocrine pancreatic dysfunction in CF
includes disturbances of water and bicarbonate secretion
but may be associated with normal enzyme output w20x.
Therefore, all methods based exclusively on the meas-
urement of pancreatic enzyme concentrationyoutput
could lead to some false negative results. Moreover, as
proven earlier, a small percentage of CF patients (at
least temporarily) have normal pancreatic function w21x.
Although E1 test is the most reliable and sensitive
indirect test used in CF children w22x, its practical value
in the assessment of mild pancreatic insufficiency is
limited w6x.
In conclusion, 184 mgyg seems to be the best cut-off
level for the E1 test in differentiating between pancreatic
insufficiency in CF and normal pancreatic function in
HS within the European population. In clinical practice,
instead of the best cut-off level, we would suggest using
a range of values (160–200 mgyg), dependent upon the
country of origin. The presence of different best cut-off
levels within countries is a practical consequence of the
different distribution of pancreatic function (resulting
from the different frequency of CFTR mutations in
populations of different origin) and is likely to be true
for all other tests of exocrine pancreatic function.
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